

53. Smith, M. T., Zhang, L., Rothman, N., Wang, Y., Hayes, R. B., Li, G. L., and Yin, S. N. Interphase cytogenetics of workers exposed to benzene. *Environ. Health Perspect.*, 105: 1325-1329, 1996.
54. Crane, M. M., Keating, M. J., Trujillo, J. M., Labarthe, D. R., and Frankowski, R. F. Environmental exposures in cytogenetically defined subsets of acute nonlymphocytic leukemia. *JAMA*, 262: 634-639, 1989.
55. Van den Berghe, H., Louwagie, A., Broeckaert-Van Orshoven, A., David, G., and Verwilghen, R. Chromosome analysis in two unusual malignant blood disorders presumably induced by benzene. *Blood*, 53: 558-566, 1979.
56. Le Beau, M. M. and Rowley, J. D. Chromosomal abnormalities in leukemia and lymphoma: clinical and biological significance. *Adv. Hum. Genet.*, 15: 1-54, 1986.
57. Stillman, W. S., Varella-Garcia, M., and Irons, R. D. The benzene metabolite, hydroquinone, selectively induces 5q31-and-7 in human CD34⁺CD19⁻ bone marrow cells. *Exp. Hematol.*, 28: 169-176, 2000.
58. Pedersen-Bjergaard, J. and Rowley, J. D. The balanced and the unbalanced chromosome aberrations of acute myeloid leukemia may develop in different ways and may contribute differently to malignant transformation. *Blood*, 83: 2780-2786, 1994.
59. Gill-Super, H., McCabe, N., and Thirman, M. Rearrangements of the MLL gene in therapy-related acute myeloid leukemia in patients previously treated with agents targeting DNA-topoisomerase II. *Blood*, 83: 2780-2786, 1993.
60. Stone, R., Neuberg, D., Soiffer, R., Whelan, M., Leavitt, P., Aster, J., Takvorian, R., Rabinowe, S., Ritz, J., Freedman, A., and Nadler, L. Myelodysplastic syndrome (MDS) as a complication after autologous bone marrow transplantation (ABMT) for nonhodgkin's lymphoma (NHL). *Blood* 82, 196a. 93.
61. Murphy, S. B. Secondary acute myeloid leukemia following treatment with epipodophyllotoxins. *J. Clin. Oncol.*, 11 : 199-201, 1993.
62. Sandoval, C., Pui, C.-H., Bowman, L. C., Heaton, D., Hurwitz, C. A., Raimondi, S. C., Behm, F. G., and Head, D. R. Secondary acute myeloid leukemia in children previously treated with alkylating agents, intercalating topoisomerase II inhibitors, and irradiation. *J. Clin. Oncol.*, 11: 1039-1045, 1993.
63. Chen, H. W. and Eastmond, D. A. Topoisomerase inhibition by phenolic metabolites: A potential mechanism for benzene's clastogenic effects. *Carcinogenesis*, 16: 2301-2307, 1995.
64. Chen, H. W., Frantz, C., and Eastmond, D. A. Inhibition of topoisomerase enzymes by phenolic metabolites: a potential mechanism for benzene's clastogenic effects. *Benzene '95: Program for the International Conference on the Toxicity, Carcinogenesis, and Epidemiology of Benzene* July 17-20. 95.